Insulinoma

Clive Grant, Kimberly Vanderveen

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Insulinoma remains a very rare tumor, and the first challenge to making the diagnosis is to consider it. Although these tumors are typically benign, they can cause severe and often bizarre symptoms. The diagnosis is established with biochemical confirmation of hypoglycemia and endogenous hyperinsulinemia after fasting, and is distinguished from the postprandial hyperinsulinemic hypoglycemia of Noninsulinoma Pancreatogenous Hyperinsulinemia Syndrome (NIPHS). Operative removal of the tumor is the mainstay of treatment, but is predicated on precise preoperative localization. Multiple imaging options are available, including: transabdominal ultrasound, computed tomography, endoscopic ultrasound (EUS), angiography with intraarterial calcium stimulation testing, and intraoperative ultrasound (IOUS). Patients with MEN-1 syndrome virtually always have multiple pancreatic neuroendocrine tumors, and evaluation and treatment of these patients is different than for sporadic disease. Surgical excision of the disease is the only cure; in the rare case of malignant disease, an aggressive surgical and multimodal approach is recommended, even for palliation of hypoglycemia.

Original languageEnglish (US)
Pages (from-to)235-252
Number of pages18
JournalCancer Treatment and Research
Volume153
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Insulinoma
Hypoglycemia
Hyperinsulinism
Multiple Endocrine Neoplasia Type 1
Neoplasms
Neuroendocrine Tumors
Fasting
Angiography
Tomography
Calcium
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Insulinoma. / Grant, Clive; Vanderveen, Kimberly.

In: Cancer Treatment and Research, Vol. 153, 2010, p. 235-252.

Research output: Contribution to journalArticle

Grant, C & Vanderveen, K 2010, 'Insulinoma', Cancer Treatment and Research, vol. 153, pp. 235-252. https://doi.org/10.1007/978-1-4419-0857-5_13
Grant, Clive ; Vanderveen, Kimberly. / Insulinoma. In: Cancer Treatment and Research. 2010 ; Vol. 153. pp. 235-252.
@article{6ec3ec89b2fb4d07849be7bee276a49a,
title = "Insulinoma",
abstract = "Insulinoma remains a very rare tumor, and the first challenge to making the diagnosis is to consider it. Although these tumors are typically benign, they can cause severe and often bizarre symptoms. The diagnosis is established with biochemical confirmation of hypoglycemia and endogenous hyperinsulinemia after fasting, and is distinguished from the postprandial hyperinsulinemic hypoglycemia of Noninsulinoma Pancreatogenous Hyperinsulinemia Syndrome (NIPHS). Operative removal of the tumor is the mainstay of treatment, but is predicated on precise preoperative localization. Multiple imaging options are available, including: transabdominal ultrasound, computed tomography, endoscopic ultrasound (EUS), angiography with intraarterial calcium stimulation testing, and intraoperative ultrasound (IOUS). Patients with MEN-1 syndrome virtually always have multiple pancreatic neuroendocrine tumors, and evaluation and treatment of these patients is different than for sporadic disease. Surgical excision of the disease is the only cure; in the rare case of malignant disease, an aggressive surgical and multimodal approach is recommended, even for palliation of hypoglycemia.",
author = "Clive Grant and Kimberly Vanderveen",
year = "2010",
doi = "10.1007/978-1-4419-0857-5_13",
language = "English (US)",
volume = "153",
pages = "235--252",
journal = "Cancer Treatment and Research",
issn = "0927-3042",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Insulinoma

AU - Grant, Clive

AU - Vanderveen, Kimberly

PY - 2010

Y1 - 2010

N2 - Insulinoma remains a very rare tumor, and the first challenge to making the diagnosis is to consider it. Although these tumors are typically benign, they can cause severe and often bizarre symptoms. The diagnosis is established with biochemical confirmation of hypoglycemia and endogenous hyperinsulinemia after fasting, and is distinguished from the postprandial hyperinsulinemic hypoglycemia of Noninsulinoma Pancreatogenous Hyperinsulinemia Syndrome (NIPHS). Operative removal of the tumor is the mainstay of treatment, but is predicated on precise preoperative localization. Multiple imaging options are available, including: transabdominal ultrasound, computed tomography, endoscopic ultrasound (EUS), angiography with intraarterial calcium stimulation testing, and intraoperative ultrasound (IOUS). Patients with MEN-1 syndrome virtually always have multiple pancreatic neuroendocrine tumors, and evaluation and treatment of these patients is different than for sporadic disease. Surgical excision of the disease is the only cure; in the rare case of malignant disease, an aggressive surgical and multimodal approach is recommended, even for palliation of hypoglycemia.

AB - Insulinoma remains a very rare tumor, and the first challenge to making the diagnosis is to consider it. Although these tumors are typically benign, they can cause severe and often bizarre symptoms. The diagnosis is established with biochemical confirmation of hypoglycemia and endogenous hyperinsulinemia after fasting, and is distinguished from the postprandial hyperinsulinemic hypoglycemia of Noninsulinoma Pancreatogenous Hyperinsulinemia Syndrome (NIPHS). Operative removal of the tumor is the mainstay of treatment, but is predicated on precise preoperative localization. Multiple imaging options are available, including: transabdominal ultrasound, computed tomography, endoscopic ultrasound (EUS), angiography with intraarterial calcium stimulation testing, and intraoperative ultrasound (IOUS). Patients with MEN-1 syndrome virtually always have multiple pancreatic neuroendocrine tumors, and evaluation and treatment of these patients is different than for sporadic disease. Surgical excision of the disease is the only cure; in the rare case of malignant disease, an aggressive surgical and multimodal approach is recommended, even for palliation of hypoglycemia.

UR - http://www.scopus.com/inward/record.url?scp=77953674758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953674758&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-0857-5_13

DO - 10.1007/978-1-4419-0857-5_13

M3 - Article

C2 - 19957228

AN - SCOPUS:77953674758

VL - 153

SP - 235

EP - 252

JO - Cancer Treatment and Research

JF - Cancer Treatment and Research

SN - 0927-3042

ER -